GlycoEra Raises $130M, Riding Interest in Protein Degraders

GlycoEra raises $130M, riding interest in protein degraders

The startup is the latest beneficiary of investors’ appetite for protein-degrading technology, which offers a way to reach drug targets other technologies can’t.

Biotech IPO slump seen dragging into 2026 as returns disappoint

By Anthony Hughes, Bloomberg Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five biotech companies raising more than $50 million have gone public so far this year, following last year’s already stunted number of 18 initial public offerings, data compiled by Bloomberg show. The debuts are far from the f…

GlycoEra secures $130m to progress IgG4-targeted protein degrader

Biotechnology company GlycoEra has closed an oversubscribed Series B financing round, raising $130m, to support the progression of its lead immunoglobulin G4 (IgG4)-targeted protein degrader through clinical proof-of-concept. The investment will help in developing the company’s pipeline of…

The proceeds are used to advance the company's leading IgG4 protein depletor through clinical data in patients.

GlycoEra Secures $130 Million Series B Funding to Advance Extracellular Protein Degradation Technology

Biotechnology startup GlycoEra has secured $130 million […] The post GlycoEra Secures $130 Million Series B Funding to Advance Extracellular Protein Degradation Technology first appeared on GeneOnline News. The post GlycoEra Secures $130 Million Series B Funding to Advance Extracellular Protein Degradation Technology appeared first on GeneOnline News.

Investors pump $130M into protein degrader startup GlycoEra

Protein degrader shop GlycoEra, spun out of vaccines company LimmaTech in 2021, has corralled $130 million in Series B funding to get into the clinic. The transatlantic outfit's experimental medicines aim to deplete circulating proteins ...